Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Schroeder, Brett A., Kohli, Karan, O’Malley, Ryan B., Kim, Theresa S., Jones, Robin L., Pierce, Robert H., Pollack, Seth M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2020
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6959429/
https://ncbi.nlm.nih.gov/pubmed/32002307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1710064
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi